Tamoxifen and somatostatin affect tumours by inducing apoptosis

Cancer Lett. 1995 Sep 4;96(1):141-5. doi: 10.1016/0304-3835(95)03924-l.

Abstract

Tamoxifen is a commonly used chemotherapeutic agent in human breast cancer, although some tumours develop resistance. Somatostatin is also being introduced as an anti-tumour agent. Here we show that the action of these drugs is, at least partly, due to their induction of apoptosis. Both 50 nM somatostatin, and 60 nM tamoxifen significantly enhanced the percentage of cells undergoing apoptosis, when compared to untreated or oestrogen treated control cells. This effect was observed in SK-N-BE(2) human neuroblastoma cells and in MCF-7G human breast cancer cells but not in their drug-resistant counterpart MCF-7A which showed a very low rate of spontaneous programmed cell death. Finally, we propose a simple test of the sensitivity and resistance of individual tumours to these agents by assessing their ability to induce apoptosis in vitro as measured by flow cytometry.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Breast Neoplasms / pathology*
  • DNA Damage
  • DNA, Neoplasm / chemistry
  • DNA, Neoplasm / metabolism
  • Female
  • Humans
  • In Vitro Techniques
  • Neuroblastoma / pathology*
  • Somatostatin / pharmacology*
  • Tamoxifen / pharmacology*
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • DNA, Neoplasm
  • Tamoxifen
  • Somatostatin